243 related articles for article (PubMed ID: 30605883)
21. Antibiotics attenuate diet-induced nonalcoholic fatty liver disease without altering intestinal barrier dysfunction.
Brandt A; Csarmann K; Hernández-Arriaga A; Baumann A; Staltner R; Halilbasic E; Trauner M; Camarinha-Silva A; Bergheim I
J Nutr Biochem; 2024 Jan; 123():109495. PubMed ID: 37871765
[TBL] [Abstract][Full Text] [Related]
22. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
Mouries J; Brescia P; Silvestri A; Spadoni I; Sorribas M; Wiest R; Mileti E; Galbiati M; Invernizzi P; Adorini L; Penna G; Rescigno M
J Hepatol; 2019 Dec; 71(6):1216-1228. PubMed ID: 31419514
[TBL] [Abstract][Full Text] [Related]
23. Loss of lipopolysaccharide-binding protein attenuates the development of diet-induced non-alcoholic fatty liver disease in mice.
Jin CJ; Engstler AJ; Ziegenhardt D; Bischoff SC; Trautwein C; Bergheim I
J Gastroenterol Hepatol; 2017 Mar; 32(3):708-715. PubMed ID: 27404046
[TBL] [Abstract][Full Text] [Related]
24. Treatment with alpha-galactosylceramide protects mice from early onset of nonalcoholic steatohepatitis: Role of intestinal barrier function.
Engstler AJ; Sellmann C; Jin CJ; Brandt A; Herz K; Priebs J; Bergheim I
Mol Nutr Food Res; 2017 May; 61(5):. PubMed ID: 28067024
[TBL] [Abstract][Full Text] [Related]
25. Involvement of G protein-coupled receptor kinase 2 (GRK2) in the development of non-alcoholic steatosis and steatohepatitis in mice and humans.
Cruces-Sande M; Vila-Bedmar R; Arcones AC; González-Rodríguez Á; Rada P; Gutiérrez-de-Juan V; Vargas-Castrillón J; Iruzubieta P; Sánchez-González C; Formentini L; Crespo J; García-Monzón C; Martínez-Chantar ML; Valverde ÁM; Mayor F; Murga C
Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3655-3667. PubMed ID: 30261289
[TBL] [Abstract][Full Text] [Related]
26. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose.
Sun G; Jackson CV; Zimmerman K; Zhang LK; Finnearty CM; Sandusky GE; Zhang G; Peterson RG; Wang YJ
BMC Gastroenterol; 2019 Mar; 19(1):41. PubMed ID: 30885145
[TBL] [Abstract][Full Text] [Related]
27. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
28. Protective effect of salvianolic acid B on NASH rat liver through restoring intestinal mucosal barrier function.
Wang YC; Jin QM; Kong WZ; Chen J
Int J Clin Exp Pathol; 2015; 8(5):5203-9. PubMed ID: 26191218
[TBL] [Abstract][Full Text] [Related]
29. Non-Alcoholic Fatty Liver Disease in Overweight Children: Role of Fructose Intake and Dietary Pattern.
Nier A; Brandt A; Conzelmann IB; Özel Y; Bergheim I
Nutrients; 2018 Sep; 10(9):. PubMed ID: 30235828
[TBL] [Abstract][Full Text] [Related]
30. Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier.
Zhou D; Pan Q; Xin FZ; Zhang RN; He CX; Chen GY; Liu C; Chen YW; Fan JG
World J Gastroenterol; 2017 Jan; 23(1):60-75. PubMed ID: 28104981
[TBL] [Abstract][Full Text] [Related]
31. Sodium butyrate protects mice from the development of the early signs of non-alcoholic fatty liver disease: role of melatonin and lipid peroxidation.
Jin CJ; Engstler AJ; Sellmann C; Ziegenhardt D; Landmann M; Kanuri G; Lounis H; Schröder M; Vetter W; Bergheim I
Br J Nutr; 2016 Nov; 116(10):1682-1693. PubMed ID: 27876107
[TBL] [Abstract][Full Text] [Related]
32. Glycine protects against high sucrose and high fat-induced non-alcoholic steatohepatitis in rats.
Zhou X; Han D; Xu R; Wu H; Qu C; Wang F; Wang X; Zhao Y
Oncotarget; 2016 Dec; 7(49):80223-80237. PubMed ID: 27784003
[TBL] [Abstract][Full Text] [Related]
33. Western diet-induced increase in colonic bile acids compromises epithelial barrier in nonalcoholic steatohepatitis.
Gupta B; Liu Y; Chopyk DM; Rai RP; Desai C; Kumar P; Farris AB; Nusrat A; Parkos CA; Anania FA; Raeman R
FASEB J; 2020 May; 34(5):7089-7102. PubMed ID: 32275114
[TBL] [Abstract][Full Text] [Related]
34. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
35. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice.
Spruss A; Kanuri G; Wagnerberger S; Haub S; Bischoff SC; Bergheim I
Hepatology; 2009 Oct; 50(4):1094-104. PubMed ID: 19637282
[TBL] [Abstract][Full Text] [Related]
36. Metformin protects against the development of fructose-induced steatosis in mice: role of the intestinal barrier function.
Spruss A; Kanuri G; Stahl C; Bischoff SC; Bergheim I
Lab Invest; 2012 Jul; 92(7):1020-32. PubMed ID: 22525431
[TBL] [Abstract][Full Text] [Related]
37. Coffee Restores Expression of lncRNAs Involved in Steatosis and Fibrosis in a Mouse Model of NAFLD.
Di Mauro S; Salomone F; Scamporrino A; Filippello A; Morisco F; Guido M; Lembo V; Cossiga V; Pipitone RM; Grimaudo S; Malaguarnera R; Purrello F; Piro S
Nutrients; 2021 Aug; 13(9):. PubMed ID: 34578828
[TBL] [Abstract][Full Text] [Related]
38. Mesenteric adipose tissue contributes to intestinal barrier integrity and protects against nonalcoholic fatty liver disease in mice.
Wu Z; Tan J; Chi Y; Zhang F; Xu J; Song Y; Cong X; Wu N; Liu Y
Am J Physiol Gastrointest Liver Physiol; 2018 Nov; 315(5):G659-G670. PubMed ID: 29902065
[TBL] [Abstract][Full Text] [Related]
39. Hepatocyte apoptosis is tumor promoting in murine nonalcoholic steatohepatitis.
Hirsova P; Bohm F; Dohnalkova E; Nozickova B; Heikenwalder M; Gores GJ; Weber A
Cell Death Dis; 2020 Feb; 11(2):80. PubMed ID: 32015322
[TBL] [Abstract][Full Text] [Related]
40. Lowering the dietary omega-6: omega-3 does not hinder nonalcoholic fatty-liver disease development in a murine model.
Enos RT; Velázquez KT; McClellan JL; Cranford TL; Walla MD; Murphy EA
Nutr Res; 2015 May; 35(5):449-59. PubMed ID: 25934114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
